Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginInterest Coverage RatioInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on SalesTimes Interest Earned

Kymera Therapeutics (KYMR) FCF Margin (2019 - 2026)

Kymera Therapeutics (KYMR) has disclosed FCF Margin for 8 consecutive years, with 259.78% as the latest value for Q1 2026.

  • For Q1 2026, FCF Margin rose 10048.0% year-over-year to 259.78%; the TTM value through Mar 2026 reached 474.01%, down 6650.0%, while the annual FY2025 figure was 597.64%, 15717.0% down from the prior year.
  • FCF Margin hit 259.78% in Q1 2026 for Kymera Therapeutics, up from 2329.37% in the prior quarter.
  • Across five years, FCF Margin topped out at 7.48% in Q4 2023 and bottomed at 2329.37% in Q4 2025.
  • Average FCF Margin over 5 years is 606.65%, with a median of 423.79% recorded in 2022.
  • On a YoY basis, FCF Margin climbed as much as 34919bps in 2025 and fell as far as -148112bps in 2025.
  • Kymera Therapeutics' FCF Margin stood at 247.28% in 2022, then skyrocketed by 97bps to 7.48% in 2023, then plummeted by -11246bps to 848.26% in 2024, then plummeted by -175bps to 2329.37% in 2025, then surged by 89bps to 259.78% in 2026.
  • According to Business Quant data, FCF Margin over the past three periods came in at 259.78%, 2329.37%, and 987.37% for Q1 2026, Q4 2025, and Q3 2025 respectively.